In a major safety move, the government has restricted all fixed-dose combinations containing Chlorpheniramine Maleate and Phenylephrine Hydrochloride for children under four. Manufacturers must now include explicit warning labels on all packaging.

  • Restrictions imposed on Chlorpheniramine Maleate and Phenylephrine Hydrochloride combinations.
  • Mandatory warning labels required for formulations involving these chemicals.
  • Prohibited for use in children below four years of age.
  • Decision backed by the Drugs Technical Advisory Board (DTAB).

In a significant move to safeguard the health and safety of young children, the Indian government has imposed strict restrictions on the manufacture, sale, and distribution of all Fixed Dose Combinations (FDCs) containing Chlorpheniramine Maleate and Phenylephrine Hydrochloride. The latest regulatory notification mandates that these medicines must carry a clear warning stating they shall not be used in children below four years of age.

The decision follows rigorous recommendations from an expert committee and the Drugs Technical Advisory Board (DTAB). The government highlighted that the use of such combinations poses potential health risks to toddlers, especially when safer pharmacological alternatives are readily available in the market.

Read Also:Jyotika Highlights Age‑Related Protein Needs: 1 Gram per Kg Essential

Why This Matters

BozokMedia analysis shows that regulating multi-ingredient drugs for pediatrics is crucial to prevent adverse drug reactions. Small children have different metabolic rates, and the combination of antihistamines and decongestants can lead to unforeseen side effects if not strictly monitored by medical professionals.

Strict regulatory oversight on pediatric formulations is the first line of defense against accidental toxicity in infants.

This latest notification expands upon a previous mandate issued on April 15, 2025, which only covered certain specific combinations. The current directive is more comprehensive, extending the restriction to all formulations containing these two specific chemical ingredients. This action has been taken under Section 26A of the Drugs and Cosmetics Act, 1940.

Historical Background

The regulation of Fixed Dose Combinations (FDCs) has been a recurring theme in Indian pharmaceutical policy. The government has frequently reviewed FDCs to ensure they provide therapeutic benefit without unnecessary risk. The Drugs and Cosmetics Act of 1940 serves as the primary legal framework for ensuring that medicines sold in India meet stringent safety and efficacy standards.

Did You Know?: Many common cough and cold medicines are 'fixed dose,' meaning they combine multiple active ingredients into a single pill or syrup.

Frequently Asked Questions

1. Which specific chemicals are subject to these new restrictions?
The restrictions apply to formulations containing Chlorpheniramine Maleate and Phenylephrine Hydrochloride.

2. What must manufacturers do according to the new rule?
Manufacturers must clearly display a warning on labels, package inserts, and promotional literature regarding the age restriction.